• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[左心室辅助装置患者的麻醉:非心脏手术期间永久性左心室辅助装置患者的麻醉管理]

[Anesthesia in patients with left ventricular assist devices : Anesthesiological management of patients with permanent left ventricular assist devices during noncardiac surgery].

作者信息

Billig Sebastian, Uhlig Moritz, Habigt Moriz A, Hein Marc

机构信息

Universitätsklinikum Aachen, Pauwelsstraße 30, 52074, Aachen, Deutschland.

出版信息

Anaesthesiologie. 2025 Aug 14. doi: 10.1007/s00101-025-01565-y.

DOI:10.1007/s00101-025-01565-y
PMID:40810786
Abstract

For patients with end-stage heart failure durable left ventricular assist devices (LVADs) are increasingly being used as an alternative to heart transplantation. Treatment with LVADs significantly improves both the survival rate and quality of life. The increasing prevalence of heart failure, particularly in older patients, combined with improved survival under LVAD therapy, has led to a growing population of LVAD recipients. As a result, anesthesiologists are increasingly faced with the challenge of providing specialized care for LVAD recipients. While elective procedures are mostly performed in specialized centers, emergency surgery can be required in any hospital. This article highlights the unique aspects in anesthesiological and perioperative management for LVAD patients undergoing noncardiac surgical procedures and interventions. Pathophysiological changes due to LVAD support as well as the obligatory anticoagulation, contribute to an increased risk of (spontaneous) bleeding complications in LVAD patients. Based on the only currently approved LVAD in Germany, the HeartMate 3, this article explains key LVAD operating parameters and discusses typical complications. Perioperative management must address the frequently impaired right ventricular function and ensure an appropriate hemodynamic monitoring. This article provides an overview of the perioperative care of LVAD patients to enhance their safety throughout the perioperative course.

摘要

对于终末期心力衰竭患者,耐用的左心室辅助装置(LVAD)越来越多地被用作心脏移植的替代方案。LVAD治疗显著提高了生存率和生活质量。心力衰竭的患病率不断上升,尤其是在老年患者中,再加上LVAD治疗下生存率的提高,导致LVAD接受者的数量不断增加。因此,麻醉医生越来越面临为LVAD接受者提供专科护理的挑战。虽然择期手术大多在专科中心进行,但任何医院都可能需要进行急诊手术。本文重点介绍了接受非心脏外科手术和干预的LVAD患者在麻醉和围手术期管理中的独特方面。LVAD支持导致的病理生理变化以及必要的抗凝治疗,增加了LVAD患者(自发性)出血并发症的风险。基于德国目前唯一获批的LVAD——HeartMate 3,本文解释了LVAD的关键操作参数并讨论了典型并发症。围手术期管理必须应对常出现的右心室功能受损问题,并确保进行适当的血流动力学监测。本文概述了LVAD患者的围手术期护理,以提高他们在整个围手术期的安全性。

相似文献

1
[Anesthesia in patients with left ventricular assist devices : Anesthesiological management of patients with permanent left ventricular assist devices during noncardiac surgery].[左心室辅助装置患者的麻醉:非心脏手术期间永久性左心室辅助装置患者的麻醉管理]
Anaesthesiologie. 2025 Aug 14. doi: 10.1007/s00101-025-01565-y.
2
The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluation.终末期心力衰竭患者使用左心室辅助装置的临床疗效及成本效益:一项系统评价与经济学评估
Health Technol Assess. 2005 Nov;9(45):1-132, iii-iv. doi: 10.3310/hta9450.
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
4
Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for advanced heart failure: systematic review and economic evaluation.左心室辅助装置作为晚期心力衰竭的终末期治疗的临床和成本效益:系统评价和经济评估。
Health Technol Assess. 2024 Aug;28(38):1-237. doi: 10.3310/MLFA4009.
5
Is There an Association Between Living in a Rural Area and the Incidence of Postoperative Complications or Hospital Readmissions Following Left Ventricular Assist Device (LVAD) Implantation, Compared to Urban Lvad Recipients? A Systematic Review.与城市左心室辅助装置(LVAD)接受者相比,农村地区居民在LVAD植入术后的并发症发生率或再次入院率之间是否存在关联?一项系统评价。
Clin Cardiol. 2025 Jan;48(1):e70068. doi: 10.1002/clc.70068.
6
Left ventricular assist devices for treatment of refractory advanced heart failure: the Western Australian experience.左心室辅助装置治疗难治性晚期心力衰竭:西澳大利亚的经验。
Intern Med J. 2024 Mar;54(3):438-445. doi: 10.1111/imj.16212. Epub 2023 Aug 24.
7
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
8
Cost-Effectiveness of Left Ventricular Assist Device for Transplant-Ineligible Patients.左心室辅助装置用于不符合移植条件患者的成本效益分析
JAMA Netw Open. 2025 Apr 1;8(4):e254483. doi: 10.1001/jamanetworkopen.2025.4483.
9
Left Atrial Reverse Remodeling in Patients Supported With Durable Left Ventricular Assist Devices and Clinical Implications.接受长期左心室辅助装置支持的患者的左心房逆向重构及其临床意义
Circ Heart Fail. 2025 Jul;18(7):e012807. doi: 10.1161/CIRCHEARTFAILURE.125.012807. Epub 2025 May 13.
10
Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model.第二代和第三代左心室辅助装置作为适合心脏移植的成人移植桥接或替代治疗的临床效果和成本效益:系统评价和成本效益模型。
Health Technol Assess. 2013 Nov;17(53):1-499, v-vi. doi: 10.3310/hta17530.

本文引用的文献

1
The Society of Thoracic Surgeons Intermacs 2024 Annual Report: Focus on Outcomes in Younger Patients.胸外科医师协会Intermacs 2024年度报告:关注年轻患者的治疗结果
Ann Thorac Surg. 2025 Jan;119(1):34-58. doi: 10.1016/j.athoracsur.2024.10.003. Epub 2024 Oct 21.
2
2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.2024 年心脏病与中风统计数据:美国心脏协会发布的美国和全球数据报告。
Circulation. 2024 Feb 20;149(8):e347-e913. doi: 10.1161/CIR.0000000000001209. Epub 2024 Jan 24.
3
Perioperative management of patients with a ventricular assist device undergoing non-cardiac surgery.
接受非心脏手术的心室辅助装置患者的围手术期管理。
BJA Educ. 2023 Oct;23(10):406-413. doi: 10.1016/j.bjae.2023.06.003. Epub 2023 Aug 12.
4
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.《2021年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南》2023年聚焦更新
Eur Heart J. 2023 Oct 1;44(37):3627-3639. doi: 10.1093/eurheartj/ehad195.
5
Predictors of 5-Year Mortality in Patients Managed With a Magnetically Levitated Left Ventricular Assist Device.磁悬浮左心室辅助装置治疗患者 5 年死亡率的预测因素。
J Am Coll Cardiol. 2023 Aug 29;82(9):771-781. doi: 10.1016/j.jacc.2023.05.066.
6
Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society.利钠肽:在心衰诊断和管理中的作用:欧洲心脏病学会心力衰竭协会、美国心力衰竭学会和日本心力衰竭学会的科学声明。
Eur J Heart Fail. 2023 May;25(5):616-631. doi: 10.1002/ejhf.2848. Epub 2023 Apr 26.
7
Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial.在 MOMENTUM 3 随机试验中,完全磁悬浮与轴流左心室辅助装置患者的 5 年结果。
JAMA. 2022 Sep 27;328(12):1233-1242. doi: 10.1001/jama.2022.16197.
8
Association between splenic volume and pulsatility index in patients with left ventricular assist devices.左心室辅助装置患者脾脏体积与搏动指数之间的关联
Int J Artif Organs. 2021 Apr;44(4):282-287. doi: 10.1177/0391398820957019. Epub 2020 Sep 12.
9
Advanced Heart Failure Therapies for Adults With Congenital Heart Disease: JACC State-of-the-Art Review.成人先天性心脏病的心力衰竭治疗进展:美国心脏病学会的最新综述
J Am Coll Cardiol. 2019 Nov 5;74(18):2295-2312. doi: 10.1016/j.jacc.2019.09.004.
10
Passive Leg Raising After Left Ventricular Assist Device Implantation.植入左心室辅助装置后被动抬腿。
ASAIO J. 2019 Sep/Oct;65(7):656-660. doi: 10.1097/MAT.0000000000000870.